Cost-effectiveness analysis of defibrotide in the treatment of patients with severe veno-occlusive disease/sinusoidal obstructive syndrome with multiorgan dysfunction following hematopoietic cell transplantation in Spain.

David CarcedoTeresa Artola UrainAnabelle Chinea RodriguezEstefanía García TorresMarta González VicentGonzalo Gutiérrez GarcíaAlexandra Regueiro GarcíaMarcos Calvo HidalgoAlba Villacampa

Published in: Journal of medical economics (2021)

This cost-effectiveness model, adapted to the Spanish setting, showed that defibrotide is a cost-effective alternative to BSC alone in patients with severe VOD/SOS post-HCT.

Keyphrases

early onset
oxidative stress
combination therapy
cell proliferation
signaling pathway